Side-by-side · Research reference
PinealonvsSermorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft12/36 cited
BPhase 3Reviewed14/43 cited
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
Sermorelin
GHRH 1-29 fragment · Short-acting
SQ · Pre-sleep · 1×/day
01Mechanism of Action
Parameter
Pinealon
Sermorelin
Primary target
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Pituitary GHRH receptorWalker 1994
Pathway
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994
Downstream effect
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013
Feedback intact?
—
Yes — short pulse preserves feedback
Origin
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994
Antibody development
—
—
02Dosage Protocols
Parameter
Pinealon
Sermorelin
Frequency
Once daily during cycle
Once daily, pre-sleep
Lower / starter dose
2.5 mg / day
100 mcg per dose
Evidence basis
Russian clinical trials + in vitroKhavinson 2014
Phase 3 (Geref pediatric); clinical practiceWalker 1994Molteno 2013
Duration
10-day cycles, 1–2× per year
8–12 weeks per cycle
Reconstitution
Bacteriostatic water
Bacteriostatic water
Timing
No specific time
Pre-sleep, fasted preferred
Half-life
Hours
~12 min (plasma)Molteno 2013
Shorter than tesamorelin (~26 min) — simpler GHRH analogue.
04Side Effects & Safety
Parameter
Pinealon
Sermorelin
Injection site reaction
Mild irritation
Mild erythema, transient pain
Long-term safety
Limited Western data
—
Pregnancy / OB
Avoid
Avoid
Flushing / headache
—
Common transient effect
IGF-1 elevation
—
Modest at standard doses
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis)
Glucose handling
—
Generally neutral
Absolute Contraindications
Pinealon
- ·Pregnancy / breastfeeding
Sermorelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
Sermorelin
- ·Untreated diabetes
05Administration Protocol
Parameter
Pinealon
Sermorelin
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Injection site
SQ — abdomen preferred.
SQ — abdomen or thigh. Rotate sites.
3. Timing
Daily during cycle, any time.
Pre-sleep, fasted.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation
Sermorelin
+ Ipamorelin
StrongSermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.
- Sermorelin
- 200–300 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition